CRON
Price
$2.47
Change
-$0.01 (-0.40%)
Updated
Nov 28 closing price
Capitalization
936.26M
94 days until earnings call
Intraday BUY SELL Signals
TLRY
Price
$0.81
Change
-$0.22 (-21.36%)
Updated
Nov 28 closing price
Capitalization
943.08M
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRON vs TLRY

Header iconCRON vs TLRY Comparison
Open Charts CRON vs TLRYBanner chart's image
Cronos Group
Price$2.47
Change-$0.01 (-0.40%)
Volume$301.75K
Capitalization936.26M
Tilray Brands
Price$0.81
Change-$0.22 (-21.36%)
Volume$98.56M
Capitalization943.08M
CRON vs TLRY Comparison Chart in %
CRON
Daily Signal:
Gain/Loss:
TLRY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRON vs. TLRY commentary
Nov 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRON is a StrongBuy and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 29, 2025
Stock price -- (CRON: $2.47 vs. TLRY: $0.81)
Brand notoriety: CRON: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRON: 15% vs. TLRY: 131%
Market capitalization -- CRON: $936.26M vs. TLRY: $943.08M
CRON [@Pharmaceuticals: Generic] is valued at $936.26M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $943.08M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRON’s FA Score shows that 1 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • CRON’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, CRON is a better buy in the long-term than TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRON’s TA Score shows that 3 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • CRON’s TA Score: 3 bullish, 5 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TLRY is a better buy in the short-term than CRON.

Price Growth

CRON (@Pharmaceuticals: Generic) experienced а +4.22% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -10.25% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.90%. For the same industry, the average monthly price growth was -2.36%, and the average quarterly price growth was +17.65%.

Reported Earning Dates

CRON is expected to report earnings on Mar 03, 2026.

TLRY is expected to report earnings on Jan 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.90% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($943M) and CRON($936M) have the same market capitalization . CRON YTD gains are higher at: 22.277 vs. TLRY (-38.872). CRON has higher annual earnings (EBITDA): -25.58M vs. TLRY (-2.11B). CRON has more cash in the bank: 834M vs. TLRY (265M). CRON has less debt than TLRY: CRON (2.01M) vs TLRY (324M). TLRY has higher revenues than CRON: TLRY (831M) vs CRON (130M).
CRONTLRYCRON / TLRY
Capitalization936M943M99%
EBITDA-25.58M-2.11B1%
Gain YTD22.277-38.872-57%
P/E Ratio22.59N/A-
Revenue130M831M16%
Total Cash834M265M315%
Total Debt2.01M324M1%
FUNDAMENTALS RATINGS
CRON vs TLRY: Fundamental Ratings
CRON
TLRY
OUTLOOK RATING
1..100
193
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8597
PRICE GROWTH RATING
1..100
5054
P/E GROWTH RATING
1..100
2093
SEASONALITY SCORE
1..100
5047

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (50) in the Biotechnology industry is in the same range as CRON (58) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to CRON’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to CRON’s over the last 12 months.

CRON's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as TLRY (97) in the Biotechnology industry. This means that CRON’s stock grew similarly to TLRY’s over the last 12 months.

CRON's Price Growth Rating (50) in the Pharmaceuticals Other industry is in the same range as TLRY (54) in the Biotechnology industry. This means that CRON’s stock grew similarly to TLRY’s over the last 12 months.

CRON's P/E Growth Rating (20) in the Pharmaceuticals Other industry is significantly better than the same rating for TLRY (93) in the Biotechnology industry. This means that CRON’s stock grew significantly faster than TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRONTLRY
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CRON
Daily Signal:
Gain/Loss:
TLRY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTAAX12.84N/A
N/A
Fidelity Advisor Asset Manager 30% A
LCBOX31.99N/A
N/A
ClearBridge Dividend Strategy 1
WRAAX13.97N/A
N/A
Wilmington Global Alpha Equities A
EGORX20.93N/A
N/A
Allspring Large Cap Core R6
TSMDX16.03N/A
N/A
Trillium ESG Small/Mid Cap Institutional

CRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRON
1D Price
Change %
CRON100%
-0.40%
SNDL - CRON
73%
Closely correlated
+1.15%
TLRY - CRON
66%
Closely correlated
-21.07%
CGC - CRON
61%
Loosely correlated
-3.31%
OGI - CRON
60%
Loosely correlated
+1.86%
ACB - CRON
60%
Loosely correlated
+0.22%
More